Cargando...
Relapsed or primary refractory AML: moving past MEC and FLAG-ida
Treatment of relapsed and refractory acute myeloid leukemia (AML) is still very challenging, with poor response rates and low chance for cure. This is especially true when treating patients who are elderly, have multiple comorbidities, or who are too unfit for traditional salvage chemotherapy regime...
Guardado en:
| Publicado en: | Curr Opin Hematol |
|---|---|
| Autores principales: | , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Lippincott Williams And Wilkins
2020
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7015186/ https://ncbi.nlm.nih.gov/pubmed/31904664 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MOH.0000000000000561 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|